Tocilizumab and COVID-19: Timing of administration assessment

Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Infect Dis Now
Autors principals: Richier, Q., Jachiet, V., Bonnemains, V., Plaçais, L., Abisror, N., Garnier, M., Pacanowski, J., Dhote, R., Hinchschberger, O., Michel, M., Bienvenu, B., Comarmond, C., Lacombe, K., Mekinian, A.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Masson SAS. 2022
Matèries:
Short Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239201/
https://ncbi.nlm.nih.gov/pubmed/34198000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.idnow.2021.06.304
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars